Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

Fast Followers May Win Quicker Path To Approval

The order aims to eliminate the gap between small molecules and biologics in terms of the time to IRA-mandated Medicare negotiations, but pharma’s gain could be offset by other directives.

Small molecule developers could benefit from Trump's executive order but specifics are unclear (Shutterstock)

More from Drug Pricing

More from Market Access